Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

globenewswire.com
AZN AstraZeneca's ULTOMIRIS is highlighted as a key therapy with strong patent protection and ongoing Phase III trials for IgAN, indicating significant market potential and positive outlook. IONS Ionis Pharmaceuticals is jointly developing Sefaxersen with Roche, which has shown positive Phase II results for IgAN. Roche's exercise of option indicates confidence in the drug's potential. ARWR Arrowhead Pharmaceuticals is mentioned as developing ARO-C3, a complement inhibitor. The article lists them among companies in the IgA Nephropathy market, but provides no specific details on their drug's performance or outlook. REGN Regeneron Pharmaceuticals is mentioned as developing Pozelimab + Cemdisiran. The article lists them among companies in the PNH market, but provides no specific details on their drug's performance or outlook. SNY Sanofi's Riliprubart is in Phase III for CIDP, targeting patients refractory to standard care. This advanced stage and specific patient population suggest a positive market entry potential. OMER Omeros' Zaltenibart has received Orphan Drug Designation from the FDA for PNH and is in clinical studies. Its mechanism of inhibiting MASP-3 without affecting the classical pathway is highlighted positively.

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight New York, USA, April 30, 2026 (GLOBE NEWSWIRE) -- Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel therapeutic development. Increased awareness among clinicians and the approval of new agents such as ULTOMIRIS [AstraZeneca (Alexion Pharmaceuticals)], Sefaxersen (F. Hoffmann-La Roche/Ionis Pharmaceuticals), KP104 (Kira Pharmaceuticals), Ruxoprubart (NM8074) (NovelMed Therapeutics), Riliprubart (Sanofi), AMY-101 (Amyndas Pharmaceuticals), and others are broadening treatment options, collectively accelerating market expansion.

Recently published Complement Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as IgA Nephropathy (IgAN), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Paroxysmal Nocturnal Hemoglobinuria (PNH), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Atypical Hemolytic Uremic Syndrome (aHUS), Complement 3 Glomerulopathy (C3G), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging complement inhibitors, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the Complement Inhibitors Market Report

Discover C5 inhibitor market growth projections @ https://www.delveinsight.com/sample-request/complement-inhibitors-market-forecast

Key Factors Driving the Complement Inhibitors Market

Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, commented that as newer generations of complement inhibitors target different aspects of the complement cascade (e.g., proximal vs. terminal inhibition), the potential to develop more effective and safer treatments is growing.

Complement Inhibitors Market Analysis

Learn more about the global complement inhibitors CAGR outlook @ Complement Inhibitors Analysis

Complement Inhibitors Competitive Landscape

Some of the complement inhibitors under development include ULTOMIRIS (ravulizumab) [AstraZeneca (Alexion Pharmaceuticals)], Sefaxersen (RG6299; IONIS-FB-LRx) (F. Hoffmann-La Roche/Ionis Pharmaceuticals), ARO-C3 (Arrowhead Pharmaceuticals), KP104 (Kira Pharmaceuticals), Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Ruxoprubart (NM8074) (NovelMed Therapeutics), Riliprubart (Sanofi), AMY-101 (Amyndas Pharmaceuticals), and others.

AstraZeneca’s ULTOMIRIS (ravulizumab) is an extended-duration monoclonal antibody designed to block the C5 protein within the terminal complement cascade, enabling rapid, complete, and durable complement inhibition. By acting on this pathway, ULTOMIRIS helps reduce excessive immune system activation that may otherwise harm healthy cells. The therapy is currently under investigation in the Phase III ICAN clinical trial for the treatment of IgAN. It is also covered by patent protection in key global markets, with expected expiry in the United States in 2035 (extendable to 2038), in the European Union through 2035 (with extensions to 2038–2040), and in Japan until 2038.

Roche and Ionis Pharmaceuticals are jointly developing Sefaxersen (RG6299; IONIS-FB-LRx), an antisense oligonucleotide designed to reduce complement factor B gene expression by targeting factor B mRNA. It is the first ASO aimed at selective complement pathway suppression in IgAN. In July 2022, Roche exercised its option to license IONIS-FB-LRx following positive Phase II results. Roche is now responsible for global development, regulatory, and commercialization activities and associated costs, excluding the open-label Phase II study in patients with IgAN, which remains under Ionis’ conduct and funding.

Omeros’ Zaltenibart (OMS906) is a humanized monoclonal antibody designed to inhibit mannan-binding lectin-associated serine protease-3 (MASP-3), a primary activator of the complement alternative pathway. This pathway plays a role in numerous diseases, including conditions addressed by approved and emerging alternative pathway inhibitors. Unlike C3 and C5 inhibitors, blocking MASP-3 does not disrupt the lytic function of the classical complement pathway, which remains essential for the body’s adaptive immune defense against infections.

In a single-ascending-dose Phase I trial involving healthy volunteers, the therapy demonstrated good tolerability with no notable safety concerns. The FDA has granted Orphan Drug Designation (ODD) to Zaltenibart (OMS906) for the treatment of Paroxysmal Nocturnal Hemoglobinuria. At present, two open-label, multicenter clinical studies are underway to assess the drug in adult patients with Paroxysmal Nocturnal Hemoglobinuria.

NovelMed Therapeutics’ Ruxoprubart (NM8074) is an anti-Bb monoclonal antibody designed to selectively inhibit the alternative complement pathway while preserving the classical pathway, which remains essential for infection clearance. In a Phase I study involving 40 healthy volunteers, the therapy demonstrated a favorable safety profile, was well tolerated at all tested dose levels, and achieved complete inhibition of the alternative pathway, with longer inhibition durations observed at higher doses.

The drug is currently being evaluated in a Phase II trial in treatment-naive paroxysmal nocturnal hemoglobinuria (PNH) patients, where early findings appear encouraging. Beyond PNH, Ruxoprubart may also have therapeutic potential in other diseases driven by dysregulation of the alternative complement pathway. The U.S. Food and Drug Administration has authorized Phase Ib/II clinical studies for PNH, C3 Glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and most recently, ANCA-associated vasculitis (AAV).

Sanofi’s investigational humanized IgG4 monoclonal antibody, Riliprubart, is designed to selectively block activated C1s, a serine protease involved in the classical complement pathway. The therapy is currently in Phase III clinical development for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), particularly in patients who are refractory to standard of care (SoC) treatments or receiving Intravenous Immunoglobulin (IVIg) therapy.

The anticipated launch of these emerging therapies are poised to transform the complement inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the complement inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about who are the leading companies in complement inhibitors, visit @ Complement Inhibitors Treatment

Recent Developments in the Complement Inhibitors Market

What are Complement Inhibitors?

Complement inhibitors are a class of therapeutic agents designed to regulate or block the activity of the complement system, a key component of the innate immune response that helps the body fight infections and clear damaged cells. While essential for normal immunity, uncontrolled or excessive complement activation can lead to inflammation, tissue injury, and the progression of various autoimmune, hematologic, renal, and neurological disorders. Complement inhibitors work by targeting specific proteins within the complement cascade, such as C1s, C3, C5, factor B, or factor D, to prevent downstream inflammatory responses and cell destruction. These therapies have emerged as an important treatment approach for diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis, geographic atrophy, and other complement-mediated conditions.

Complement Inhibitors Epidemiology Segmentation

The complement inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. The complement inhibitor target patient pool is segmented into:

Scope of the Complement Inhibitors Market Report

Discover more about upcoming complement inhibitors in 2026 @ Complement Inhibitors Clinical Trials

Table of Contents

Related Reports

IgA Nephropathy Market Report

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gMG companies, including Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca (Alexion Pharmaceuticals), F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, and others.

Complement 3 Glomerulopathy Market

Complement 3 Glomerulopathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key C3G companies, including Novartis, Apellis Pharmaceuticals, Sobi, Kira Pharmaceuticals, Novo Nordisk, Omeros Corporation, Arrowhead Pharmaceuticals, and others.

Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNH companies, including Hoffmann-La Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, and others.

Chronic Inflammatory Demyelinating Polyneuropathy Market

Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CIDP companies, including Sanofi, Janssen Research and Development, LLC, Immunovant Sciences GmbH/HanAll Pharma, Roivant Sciences, Inc., and others.

Immune Complex Membranoproliferative Glomerulonephritis Market

Immune Complex Membranoproliferative Glomerulonephritis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IC-MPGN companies, including Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.